Financial Sense Advisors Inc. bought a new position in Allergan plc (NYSE:AGN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 13,652 shares of the company’s stock, valued at approximately $2,600,000. Allergan makes up about 1.1% of Financial Sense Advisors Inc.’s portfolio, making the stock its 18th biggest position.
Several other institutional investors and hedge funds have also recently modified their holdings of AGN. Edgewood Management LLC lifted its holdings in shares of Allergan by 2.6% in the 2nd quarter. Edgewood Management LLC now owns 5,728,391 shares of the company’s stock worth $955,037,000 after purchasing an additional 144,282 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Allergan by 16.3% in the 2nd quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock worth $796,712,000 after purchasing an additional 668,343 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Allergan by 1.7% in the 2nd quarter. Northern Trust Corp now owns 4,163,556 shares of the company’s stock worth $694,149,000 after purchasing an additional 69,651 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Allergan by 2.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,545,557 shares of the company’s stock worth $591,116,000 after purchasing an additional 99,490 shares during the last quarter. Finally, Parnassus Investments CA lifted its holdings in shares of Allergan by 3.1% in the 2nd quarter. Parnassus Investments CA now owns 1,844,804 shares of the company’s stock worth $307,566,000 after purchasing an additional 55,029 shares during the last quarter. Institutional investors own 77.58% of the company’s stock.
In other news, Director Christopher J. Coughlin purchased 10,000 shares of the stock in a transaction dated Thursday, September 6th. The shares were bought at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Joseph H. Boccuzi purchased 900 shares of the stock in a transaction dated Thursday, August 30th. The shares were purchased at an average price of $190.59 per share, for a total transaction of $171,531.00. The disclosure for this purchase can be found here. 0.36% of the stock is owned by insiders.
AGN has been the topic of several recent research reports. Zacks Investment Research raised Allergan from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a report on Wednesday, July 11th. Raymond James reissued a “buy” rating and issued a $232.00 price target (up previously from $211.00) on shares of Allergan in a report on Monday, September 17th. ValuEngine downgraded Allergan from a “hold” rating to a “sell” rating in a report on Wednesday. Deutsche Bank set a $210.00 price target on Allergan and gave the stock a “buy” rating in a report on Wednesday, September 12th. Finally, Cowen set a $255.00 price target on Allergan and gave the stock a “buy” rating in a report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have given a buy rating to the company’s stock. Allergan presently has a consensus rating of “Buy” and an average price target of $210.18.
Shares of Allergan stock opened at $163.05 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.85 and a current ratio of 0.92. The firm has a market cap of $55.35 billion, a price-to-earnings ratio of 9.44, a price-to-earnings-growth ratio of 1.29 and a beta of 1.31. Allergan plc has a 1-year low of $142.81 and a 1-year high of $197.00.
Allergan (NYSE:AGN) last announced its earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.21. The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.89 billion. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.15 EPS. On average, research analysts forecast that Allergan plc will post 16.43 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 14th. Shareholders of record on Tuesday, November 13th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.77%. The ex-dividend date is Friday, November 9th. Allergan’s payout ratio is currently 17.61%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Further Reading: What are the reasons investors use put options?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.